China Biologic Produ (CBPO)

119.99  +1.98 (+1.68%)

After market: 120.04 +0.05 (+0.04%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

China Biologic Produ

NASDAQ:CBPO (4/20/2021, 7:09:52 PM)

After market: 120.04 +0.05 (+0.04%)

119.99

+1.98 (+1.68%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap4.72B
Shares
PE30.07
Fwd PE27.9
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

CBPO Daily chart

Company Profile

China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company's principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Company Info

China Biologic Produ

18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT

BEIJING F4 100125

P: 86-10-6598-3111

CEO: Joseph Chow

CBPO News

News Image2 years ago - Centurium CapitalChina Biologic Privatization Transaction Led by Centurium Capital Wins AVCJ "Deal of the Year - Large Cap"

/PRNewswire/ -- The Centurium Capital-led privatization of leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc. ("China...

News Image3 years ago - China Biologic Products Holdings, Inc.China Biologic Announces Completion of Going Private Transaction
News Image3 years ago - BusinessInsiderChina Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, 'China Biologic' or the 'Company'), a leading fully ...

News Image3 years ago - China Biologic Products Holdings, Inc.China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
News Image3 years ago - Market News VideoChina Biologic Products Holdings is Now Oversold (CBPO)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

News Image3 years ago - China Biologic Products Holdings, Inc.China Biologic Announces Shareholders' Approval of Merger Agreement

CBPO Twits

Here you can normally see the latest stock twits on CBPO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example